ArticleObesity science & practice2026
Metabolic Mechanisms of Modified Lingguizhugan Decoction in Obesity and Lipid Metabolism Disorders: A Multi-Omics Approach.
Article in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Mechanisms of Modified Lingguizhugan Decoction in Obesity and Lipid Metabolism Disorders: A Multi-Omics Approach.Obesity science & practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity and related metabolic disorders, including metabolic dysfunction-associated fatty liver disease, dyslipidemia, and type 2 diabetes, are pressing global health concerns. Traditional Chinese medicine, specifically modified Lingguizhugan decoction (MLGZGD), has shown promise for managing these conditions. MLGZGD contains bioactive compounds that may modulate lipid metabolism and gut microbiota, suggesting potential therapeutic benefits for obesity and associated metabolic disorders. However, the underlying mechanisms remain largely unknown. This study investigated the therapeutic effects of MLGZGD on obesity and lipid metabolism. Specifically, we sought to examine how MLGZGD influences gut microbiota, modulates lipid metabolism, and contributes to improved metabolic health using a multi-omics approach. Methods: This study identified the active compounds in MLGZGD using UPLC-Q-TOF-MS/MS. The mice were divided into four groups ( Results: In normal mice, MLGZGD significantly altered the gut microbiota composition, increasing the abundance of beneficial genera such as Conclusions: MLGZGD effectively ameliorates obesity and lipid metabolism-related disorders by reshaping the gut microbiota and modulating lipid metabolism. These findings support the therapeutic potential of MLGZGD in treating obesity and related metabolic disorders, with modulation of gut microbiota and lipid metabolism as key mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.